These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 8894581

  • 1. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates.
    Verbist L, Verhaegen J.
    Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):683-5. PubMed ID: 8894581
    [Abstract] [Full Text] [Related]

  • 2. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.
    Coque TM, Singh KV, Murray BE.
    J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152
    [Abstract] [Full Text] [Related]

  • 3. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
    Cunha BA, Qadri SM, Ueno Y, Walters EA, Domenico P.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
    [Abstract] [Full Text] [Related]

  • 4. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
    Felmingham D, Robbins MJ, Ingley K, Mathias I, Bhogal H, Leakey A, Ridgway GL, Grüneberg RN.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():43-9. PubMed ID: 9222069
    [Abstract] [Full Text] [Related]

  • 5. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
    King A, Bethune L, Phillips I.
    J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.
    Fuchs PC, Barry AL, Brown SD.
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):33-8. PubMed ID: 9990473
    [Abstract] [Full Text] [Related]

  • 7. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
    Cohen MA, Huband MD, Gage JW, Yoder SL, Roland GE, Gracheck SJ.
    J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
    [Abstract] [Full Text] [Related]

  • 8. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP, Prenna M, Mingoia M, Ripa S, Varaldo PE.
    Chemotherapy; 1998 Aug; 44(2):85-93. PubMed ID: 9551237
    [Abstract] [Full Text] [Related]

  • 9. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.
    Sefton AM, Maskell JP, Rafay AM, Whiley A, Williams JD.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():57-62. PubMed ID: 9222071
    [Abstract] [Full Text] [Related]

  • 10. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV, Ho DH, LeBlanc B, Streeter H, Dvorak T.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activity of gemifloxacin.
    King A, May J, French G, Phillips I.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
    [Abstract] [Full Text] [Related]

  • 12. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
    Dembry LM, Farrel PA, Orcutt DR, Gerrity LA, Andriole VT.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
    [Abstract] [Full Text] [Related]

  • 13. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
    Endtz HP, Mouton JW, den Hollander JG, van den Braak N, Verbrugh HA.
    Antimicrob Agents Chemother; 1997 May; 41(5):1146-9. PubMed ID: 9145886
    [Abstract] [Full Text] [Related]

  • 14. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.
    Bonilla HF, Zarins LT, Bradley SF, Kauffman CA.
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):17-21. PubMed ID: 8950524
    [Abstract] [Full Text] [Related]

  • 15. [In vitro activity of trovafloxacin (CP-99,219) against 434 bacterial strains: comparative study with other fluoroquinolones].
    Tali-Maamar H, Tebbal S, Rahal K.
    Arch Inst Pasteur Alger; 1998 Sep; 62():52-61. PubMed ID: 11256319
    [Abstract] [Full Text] [Related]

  • 16. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H.
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [Abstract] [Full Text] [Related]

  • 17. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.
    Crokaert F, Aoun M, Duchateau V, Grenier P, Vandermies A, Klastersky J.
    Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):696-8. PubMed ID: 8894585
    [No Abstract] [Full Text] [Related]

  • 19. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
    Alarcón T, Domingo D, Prieto N, Sánchez S, López-Brea M.
    Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
    [Abstract] [Full Text] [Related]

  • 20. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.